What is avatrombopag (Su Kexin) and its treatment principle explanation

Avatrombopag (Avatrombopag) is an oral small molecule drug that is a thrombopoietin receptor agonist (TPO-RA). It was first developed by Dova Pharmaceuticals in the United States and is currently approved for the treatment of thrombocytopenia in patients with chronic liver disease before elective surgery and for patients with chronic immune thrombocytopenia (ITP). Due to its convenient oral administration and relatively stable onset of action, avatrombopag has gradually become one of the important choices for clinical management of thrombocytopenia.

The therapeutic principle of avatrombopag mainly activates thrombopoietin (TPO) receptors to stimulate the proliferation and differentiation of megakaryocytes in the bone marrow, thereby promoting the production of platelets. Different from traditional methods that rely on exogenous supplementation of platelets, it can increase platelet levels through endogenous pathways, allowing patients to steadily improve their platelet counts. This mechanism not only reduces the need for platelet transfusions but also reduces the associated risk of complications.

Clinically, avatrombopag can effectively increase platelet levels and help patients reduce the risk of bleeding caused by thrombocytopenia. It is especially suitable for the management of patients with chronic liver disease before surgery or invasive procedures. At the same time, for patients with chronic ITP, avatrombopag can improve the problem of long-term platelet deficiency and reduce the occurrence of symptoms such as purpura and nosebleeds. Compared with other TPO receptor agonists, its convenience of oral administration and relatively low risk of drug interactions improve patient compliance and treatment experience.

The application of avatrombopag not only improves patients' platelet levels, but also shows significant advantages in reducing blood transfusion dependence and improving quality of life. However, it is still necessary to pay attention to individual differences during use. Doctors usually determine the specific dosage and course of treatment based on the patient's condition, baseline platelet level, and concomitant medications. Some patients may experience adverse reactions such as headache, fatigue, or increased risk of blood clots. Therefore, platelet counts should be closely monitored during treatment to reasonably assess risks and benefits to ensure medication safety.

Reference materials:https://www.drugs.com/